Grant: Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
University of British Columbia
$63,000.00
HIV Drug Resistance: Transitioning to New Sequencing Technologies
EF 2008-09
Résumé
Many different methods for assessing HIV drug resistance are currently in clinical use. However, no consensus has yet been established as to the optimal test, and there remains significant room for improvement in the speed, sensitivity, and cost-effectiveness of existing assays. We propose to develop an improved drug resistance assay based on cutting-edge ¿ultra-deep¿ sequencing technology. By analyzing patient samples with the Roche/454 GS-FLX pyrosequencing platform, we will be able to detect minority drug-resistant virus with a sensitivity unattainable by current, conventional methods. This will enable earlier detection of low-level drug resistance and improve patient outcomes by increasing the efficacy of HAART. This assay will also facilitate the detection of resistance to integrase inhibitors, a novel drug class recently approved by Health Canada. When it is validated, this will be the only test for integrase inhibitor resistance available in Canada. By adapting existing drug resistance assays to the Roche/454 technology, we will be able to provide a clinical test that is faster, more sensitive, and more cost-effective than any method currently available.
This project also aims to establish the prevalence and clinical significance of pre-existing drug resistance in HIV-positive individuals beginning treatment. The transmission of drug-resistant virus to therapy-naïve individuals is a growing concern, as the presence of such resistance has been associated with suboptimal response to antiretroviral therapy and increased risk of treatment failure. We will use conventional genotypic bulk sequencing methods to describe the drug resistance profiles of patients prior to their first antiretroviral therapy and study disease progression through testing of follow-up samples. We believe this information will be of great clinical significance in the selection of appropriate antiretroviral therapy regimens and may contribute to improved clinical outcomes for patients.
Programme
Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
182374
Name
Harrigan Richard P
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Merck Frosst Canada Inc. (Quebec)
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
HIV Drug Resistance: Transitioning to New Sequencing Technologies
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$63,000
Cihrequipment2
$0
Programname2
Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
Keyworddelim
Drug Resistance; Hiv/Aids; Integrase; Therapy; Ultra-Deep Sequencing (454 Gs Flx Sequencer)
Abstract
Many different methods for assessing HIV drug resistance are currently in clinical use. However, no consensus has yet been established as to the optimal test, and there remains significant room for improvement in the speed, sensitivity, and cost-effectiveness of existing assays. We propose to develop an improved drug resistance assay based on cutting-edge ¿ultra-deep¿ sequencing technology. By analyzing patient samples with the Roche/454 GS-FLX pyrosequencing platform, we will be able to detect minority drug-resistant virus with a sensitivity unattainable by current, conventional methods. This will enable earlier detection of low-level drug resistance and improve patient outcomes by increasing the efficacy of HAART. This assay will also facilitate the detection of resistance to integrase inhibitors, a novel drug class recently approved by Health Canada. When it is validated, this will be the only test for integrase inhibitor resistance available in Canada. By adapting existing drug resistance assays to the Roche/454 technology, we will be able to provide a clinical test that is faster, more sensitive, and more cost-effective than any method currently available.
This project also aims to establish the prevalence and clinical significance of pre-existing drug resistance in HIV-positive individuals beginning treatment. The transmission of drug-resistant virus to therapy-naïve individuals is a growing concern, as the presence of such resistance has been associated with suboptimal response to antiretroviral therapy and increased risk of treatment failure. We will use conventional genotypic bulk sequencing methods to describe the drug resistance profiles of patients prior to their first antiretroviral therapy and study disease progression through testing of follow-up samples. We believe this information will be of great clinical significance in the selection of appropriate antiretroviral therapy regimens and may contribute to improved clinical outcomes for patients.
Competitiondate
200903
Approvedterm2
1 yr 6 mths
Pinamesdelim
Harrigan, Richard P
Approvedterm
1 an 6 mois
Cihrcontribution2
Patient Oriented Research~ $63,000~ $0~